Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0236

Medical education · Dr. Benedikt Lopez

05 Jan 2026 · In person · Dr. Benedikt Lopez, Mayo Clinic · MSL Rachel Adeyemi · Aurelin

ReviewedVeeva CRMENG-0236—

Capture insight from this engagement

Location: Mayo Clinic
Therapeutic area: Immunology
Country: United States
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Aurelin (aurelinate)

Topics discussed

Phase IIb efficacy
Long-term safety monitoring

Scientific content used

JAK selectivity review
ARL Phase IIb summary

Questions raised

How does selectivity compare with approved JAK inhibitors?

Notes

Medical education with allergist at Mayo Clinic. Discussed phase iib efficacy, long-term safety monitoring.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Send publication reprint

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 2
Depth of exchange: 4
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0236

Audit history (0)

All create, update and approval events for this record

No audit events in sample data